Regulation of activin's access to the cell: Why is mother nature such a control freak?

BioEssays

Volumn 22, Issue 8, 2000, Pages 689-696

  Phillips, David J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR; CARRIER PROTEIN; GROWTH FACTOR RECEPTOR; GROWTH PROMOTOR; INHIBIN;

ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; HUMAN; METABOLISM; PROTEIN QUATERNARY STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ACTIVIN RECEPTORS; ACTIVINS; ANIMALS; CARRIER PROTEINS; GROWTH SUBSTANCES; HUMANS; INHIBINS; MODELS, BIOLOGICAL; PROTEIN STRUCTURE, QUATERNARY; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0033852903     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-1878(200008)22:8<689::AID-BIES2>3.0.CO;2-5     Document Type: Review

References (71)

1. Vale W, Rivier J, Vaughan J, McClintock R, Corrigan A, Woo W, Karr D, Spies J. Purification and characterization of an FSH releasing protein from porcine follicular fluid. Nature 1986;321:776-779.
2. Kingsley DM. The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994;8:133-146.
3. Matzuk MM, Kumar TR, Vassalli A, Bickenbach JR, Roop DR, Jaenisch R, Bradley A. Functional analysis of activins during mammalian development. Nature 1995;374:354-356.
4. Proetzel G. Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, D ng J, Ferguson MWJ, Doetschman T. Transforming growth factor-β3 is required for secondary palate fusion. Nat Genet 1995;11: 409-414.
5. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP. Cardell EL, Doetschman T. TGFβ2 knockout mice have multiple developmental defecfs that are non-overlapping with other TGFβ knockout phenotypes. Development 1997;1242:659-2670.
6. Ying S-Y, Zhang Z, Furst B, Batres Y, Huang G, Li G. Activins and activin receptors in cell growth. Proc Soc Exp Biol Med 1997;214:114-122.
7. Woodruff TK. Regulation of cellular and system function by activin Biochem Pharmacol 1998;55:953-963.
8. Gurdor JB, Harger P, Mitchell A, Lemaire P. Activin signalling and response to a morphogen gradient. Nature 1994;371:487-492.
9. Kojima I. Mogami H, Kawamura N, Yasuda H, Shibata H, Modulation of growth of vascular smooth muscle cells by activin A. Exp Cell Res 1993; 206:152-156.
10. McCarthy SA, Bicknell R. Inhibition of vascular endothelial cell growth by activin-A. J Biol Chem 1993;268:23066-23071.
11. Smith JC, Price BM, Van Nimmen K. Huylebroeck D. Identification of a potent Xenopus mesoderm-inducing factor as a homologue of activin A. Nature 1990;345:729-731.
12. Schubert D, Kimura H LaCorbiere M, Vaughan J, Karr D, Fischer WH. Activin is a nerve cell survival molecule Nature 1990;344:868-870.
13. Yu J, Shao L, Lemas V, Yu AL, Vaughan J, Rivier J, Vale W. Importance of FSH-releasing protein and inhibin in erythrodifferertiation. Nature 1987;330:765-767.
14. Nishihara T, Okahashi N, Ueda N. Activin A induces apoptotic cell death Biochem Biophys Res Commun 1993;197:985-991.
15. Dyson S, Gurdon JB. The interpretation of position in a morphogen gradient as revealed by occupancy of activin receptors. Cell 1998;93:557-568.
16. McDowell N, Gurdon JB. Activin as a morphogen in Xenopus mesoderm induction. Semin Cell Dev Biol 1999;10:311-317.
17. Feijen A Goumans MJ, van den Eijnden-van Raaij AJM. Expression of activin subunits, activin receptors ana follistatin in postimplantation mouse embryos suggests specific developmental functions for different activins. Development 1994;120:3621-3627.
18. Draper LB, Matzuk MM, Roberts VJ, Cox E, Weiss J, Mather JP. Woodruff TK. Identification of an inhibin receptor in gonadal tumors from inhibin α-subunit knockout mice. J Biol Chem 1998;273:398-403.
19. Hertan R, Farnworth PG, Fitzsimmons KL, Robertson DM. Identification of high affinity binding sites for inhibin on ovine pituitary cells in culture. Endocrinology 1999;140:6-12.
20. Malzuk MM, Finegold MJ. Mather JP, Krummen L, Lu H, Bradley A. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA 1994;91:8817-8821.
21. Coerver KA, Woodruff TK, Finegold MJ, Mather J, Bradley A, Matzuk MM. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice. Mol Endocrinol 1996; 10:534-543.
22. C chain. Biochem Biophys Res Commun 1995;206:608-613.
23. Oda S, Nishimatsu S-I, Murakami K, Ueno N. Molecular cloning and functional analysis of a new activin β subunit: a dorsal mesoderm-inducing activity in Xenopus Biochem Biophys Res Commun 1995;210:581-588.
24. E subunit gene. Biochem Biophys Res Commun 1996; 228:669-674.
25. C heterodimers. J Clin Endocrinol Metab 2000 in press.
26. Phillips DJ, de Kretser DM. Follistatin: a multifunctional regulatory protein. Front Neuroendocrinol 1998,19:287-322.
27. Sugino K, Kurosawa N, Nakamura T, Takio K, Shimasaki S, Ling N Titani K, Sugino H. Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. J Biol Chem 1993;268:15579-15587.
28. Hashimoto O, Nakamura T, Shoji H, Shimasaki S. Hayashi Y, Sugino H. A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate. J Biol Chem 1997;272:13835-13842.
29. Delbaere A, Sidis Y, Schneyer AL. Differential response to exogenous and endogenous activin in a human ovarian teratocarciroma-derived cell line (PA-1) regulation by cell surface follistatin. Endocrinology 1999;140: 2463-2470.
30. McPherson SJ, Mellor SL. Wang H. Evans LW, Groome NP, Risbridger GP. Expression of activin A and follistatin core proteins by human prostate tumor cell lines. Endocrinology 1999;140:5303-5309.
31. Schneyer AL, Hal HA, Lambert-Messerlian G, Wang QF, Sluss P, Crowley WF Jr. Follistatin-activin complexes in human serum and follicular fluid differ immunologically and biochemically. Endocrinology 1996;137:240-247.
32. Schneyer AL, Rzucidlo DA, Sluss PM, Crowley WF Jr. Characterization of unique binding kinetics of follistatin and activin or inhibin in serum. Endocrinology 1994;135:667-674.
33. 2-macroglobulin complex. Endocrinology 1995;136:5343-5349.
34. LaMarre J, Hayes MA, Wellenberg GK, Hussaini I, Hall SW, Gonias SL. An α2-mscroglobulin receptor-dependent mechanism for the plasma clearance of transforming growth factor-β1 in mice. J Clin Invest 1991; 87:39-44.
35. Hsu DR, Economides AN, Wang X, Elmon PM, Harland RM. The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol Cell 1998;1:673-683.
36. McFarlane JR, Foulds LM, O'Connor AE, Phillips DJ, Jenkin G, Hearn MTW, de Kretser DM. Uterine milk protein, a novel activin-binding protein, is present in ovine allantoic fluid. Endocrinology 1999;140: 4745-4752.
37. Iemura S-i, Yamamoto TS, Takagi C, Kobayashi H, Ueno N. Isolation and characterization of bone morphogenetic protein-binding proteins from the early Xenopus embryo. J Biol Chem 1999;274: 26843-26849.
38. Piek E, Heldin C-H, Ten Dijke P. Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J 1999;13:2105-2124.
39. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-β receptor. Nature 1994;370:341-347.
40. Attisano L, Cércamo J, Ventura F, Weis FMB, Massagué J, Wrana JL. Identification of human activin and TGFβ type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993;75:671-680.
41. Attisano L, Wrana JL, Cheifetz S, Massagué J. Novel activin receptors distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. Cell 1992;68:97-108.
42. Xu J, Matsuzak K, McKeehan K, Wang F. Kan M, McKeehan WL. Genomic structure and cloned cDNAs predict that four variants in the kinase domain of serine/threonine kinase receptors arise by alternative splicing and poly(A) addition. Proc Natl Acad Sci USA 1994;91: 7957-7961.
43. Symes K, Yordán C, Mercola M. Morphological differences in Xenopus embryonic mesodermal cells are specified as an early response to distinct threshold concentrations of activin. Development 1994;120: 2339-2346.
44. Cárcamo J, Weis FMB, Ventura F Wieser R, Wrana JL, Attisano L, Massagué J. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor β and activin. Mol Cell Biol 1994;14:3810-3821.
45. Hashmoto O, Yamato K, Koseki T, Ohguchi M, Ishisaki A, Shoji H, Nakamura T, Hayashi Y, Sugino H, Nishihara T. The role of activin type I receptors in activin A-induced growth arrest and apoptosis in mouse B-cell hybridoma cells. Cell Signal 1998;10:743-749.
46. Xu J, McKeehan K, Matsuzaki K, McKeehan WL. Inhibin antagonizes inhibition of liver cell growth by activin by a dominant-negative mechanism. J Biol Chem 1995;270:6308-6313.
47. Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM, Vale W. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 2000;404:411-414.
48. Robertson DM, Foulds LM, Prisk M, Hedger MP. Inhibin/activin β-subunit monomer: isolation and characterization. Endocrinology 1992;130: 1680-1687.
49. Hüsken-Hindi P, Tsuchida K, Park M, Corrigan AZ, Vaughan JM, Vale WW, Fischer WH. Monomeric activin A retains high receptor binding affinity but exhibits low biological activity. J Biol Chem 1994;269:19380-19384.
50. Thisse C, Thisse B. Antivin, a novel and divergent member of the TGFβ superfamily, negatively regulates mesoderm induction. Development 1999;126:229-240.
51. Onichtchouk D, Chen Y-G, Dosch R, Gawantka V, Dellus H, Massagué J. Niehrs C. Silencing of TGF-β signalling by the pseudoreceptor BAMBI Nature 1999;401:480-485.
52. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J Biol Chem 1999;274 584-594.
53. Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM. Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics 1995; 139:1347-1358.
54. Savage C, Das P, Finelli AL, Townsend SR, Sun CY, Baird SE, Padgett RW. Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor β pathway components. Proc Natl Acad Sci USA 1996;93:790-794.
55. ten Dijke P, Miyazono K, Heldin CH. Signaling inputs converge on nuclear effecters in TGF-β signaling. Trends Biochem Sci 2000;25: 64-70.
56. Shi Y, Hata A, Lo RS, Massagué J, Pavletich NP. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 1997; 388:87-93.
57. Kawabata M, Inoue H, Hanyu A, Imamura T, Miyazono K. Smad proteins exist as monomers in vivo and undergo homo-and hetero-oligomerization upon activation by serine/threonine kinase receptors. EMBO J 1998;17:4056-4065.
58. Ishisaki A, Yamato K, Nakao A, Nonaka K, Ohguchi M, ten Dijke P, Nishihara T, Smad7 is an activin-inducible inhibitor of activin-incuced growth arrest and apoptosis in mouse B cells. J Biol Chem 1998;273: 24293-24296.
59. Nagarajan RP, Zhang JM, Li W, Chen Y. Regulation of Smad7 promoter by direct association with Smad3 and Smad4. J Biol Chem 1999;274:33412-33418.
60. Shimizu K, Gurdon JB. A quantitative analysis of signal transduction from activin receptor to nucleus and its relevance to morphogen gradient interpretation. Proc Natl Acad Sci USA 1999;96:6791-6796.
61. Shoji H, Tsuchida K, Kishi H, Yamakawa N, Matsuzaki T, Liu ZH, Nakamura T. Sugino H. Identification and characterization of a PDZ protein that interacts with activin type II receptors. J Biol Chem 2000;275: 5485-5492.
62. A in rat spermatogenic cells. Biol Reprod 1999;60:588-593.
63. Jans DA, Hassan G. Nuclear targeting by growth factors, cylokines, and their receptors: a role in signaling? Bioessays 1998;20:400-411.
64. Iemura S-I, Yamamoto TS, Takagi C, Uchiyama H, Natsume T, Shimasaki S, Sugino H, Ueno N. Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc Natl Acad Sci USA 1998;95: 9337-9342.
65. Yamashita H. ten Dijke P, Huylebroeck D, Sampath TK, Andries M, Smith JC, Heldin C-H, Miyazono K. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol 1995;130: 217-226.
66. Chang C, Wilson PA. Matnews LS, Hemmati-Brivanlou A. A Xenopus type I activin receptor mediates mesodermal but not neural specification during embryogenesis. Development 1997;124:827-837.
67. Candia AF, Watabe T, Hawley SHB, Onichtchouk D, Zhang Y, Derynck R, Niehrs C, Cho KWY. Cellular interpretation of multiple TGF-β signals:intracellular antagonism between activin/BVg1 and BMP-2/4 signaling mediated by Smads. Development 1997;124: 4467-4480.
68. Matzuk MM, Lu N, Vogel H, Sellheyer K, Roop DR, Bradley A. Multiple defects and perinatal deatn in mice deficient in follistatin. Nature 1995. 374:360-363.
69. Visser JA, Themmen APN. Downstream factors in transforming growth factor-β family signaling. Mol Cell Endocrinol 1998;146:7-17.
70. Brummel T, Abdollah S, Haerry TE, Shimell MJ, Merriam J, Raftery L, Wrana JL, O'Connor MB. The Drosophila activin receptor Baboon signals through dSmad2 and controls cell proliferation but not patterning during larval development. Genes Dev 1999;13:98-111.
71. Das P, Inoue H, Baker JC, Beppu H, Kawabata M, Harland RM, Miyazono K, Padgett RW. Drosophila dSmad2 and Atr-I transmit activin/ TGFβ signals. Genes Cells 1999;4:123-134.